RxDoctor Payments Data

Harsh Agrawal, MD

Interventional Cardiology · San Francisco, CANPI 1629397674

Payments from drug & device makers

$10,885in general payments, 2019–2025

Across 169 payments — averaging $64.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Abiomed$2K
  • Cardiovascular Systems Inc.$1K
  • Boston Scientific$742
  • Cathworks, Inc.$500
  • Medtronic$430
  • plus $3K from 19 others

What the payments were for

  • Consulting fees$5005%
  • Speaking & faculty fees$1,40013%
  • Travel & lodging$2,00419%
  • Food & beverage$6,57162%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,885 in reported general payments places this provider in the 50th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$352,691
Medicare patients
944
Services billed
2,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor16$14,177
JardianceEmpagliflozin13$12,935
EliquisApixaban15$12,841
EntrestoSacubitril/Valsartan11$4,673
Ranolazine ErRanolazine13$1,349
ClopidogrelClopidogrel Bisulfate79$655
Furosemide64$336
Isosorbide Mononitrate ErIsosorbide Mononitrate16$307
Metoprolol Succinate18$267
Pantoprazole Sodium12$96
Potassium Chloride11$82
Spironolactone12$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$37$14,17716 claims
PfizerEliquis$130$12,84115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →